Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?

Leggi l'articolo originale


A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.

Lascia un commento